CCR7 and B-cell chronic lymphocytic leukemia: Our results confirm that CCR7 migration is not modulated by ibrutinib in vivo or in vitro treatments, further suggesting that T-cells trafficking to LN/spleen may be preserved in CLL patients, thus supporting the expansion hypothesis by Long et al. [14].